Biomarin Pharmaceutical Stock Price To Book
| BMRN Stock | USD 71.60 0.28 0.39% |
Biomarin Pharmaceutical fundamentals help investors to digest information that contributes to Biomarin Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Biomarin Stock. The fundamental analysis module provides a way to measure Biomarin Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomarin Pharmaceutical stock.
As of the 21st of March 2025, Price To Book Ratio is likely to grow to 3.91. Biomarin | Price To Book |
Biomarin Pharmaceutical Company Price To Book Analysis
Biomarin Pharmaceutical's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Biomarin Pharmaceutical Price To Book | 2.40 X |
Most of Biomarin Pharmaceutical's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomarin Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biomarin Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Biomarin Pharmaceutical is extremely important. It helps to project a fair market value of Biomarin Stock properly, considering its historical fundamentals such as Price To Book. Since Biomarin Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biomarin Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biomarin Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Biomarin Price To Book Historical Pattern
Today, most investors in Biomarin Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomarin Pharmaceutical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to book growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Biomarin Pharmaceutical price to book as a starting point in their analysis.
Biomarin Pharmaceutical Price To Book |
| Timeline |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Biomarin Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Biomarin Pharmaceutical has a Price To Book of 2.4048 times. This is 90.64% lower than that of the Biotechnology sector and 60.19% lower than that of the Health Care industry. The price to book for all United States stocks is 74.71% higher than that of the company.
Biomarin Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomarin Pharmaceutical's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomarin Pharmaceutical could also be used in its relative valuation, which is a method of valuing Biomarin Pharmaceutical by comparing valuation metrics of similar companies.Biomarin Pharmaceutical is currently under evaluation in price to book category among its peers.
Biomarin Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biomarin Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biomarin Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Biomarin Fundamentals
| Return On Equity | 0.0805 | ||||
| Return On Asset | 0.0515 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 13.07 B | ||||
| Shares Outstanding | 190.78 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 98.58 % | ||||
| Number Of Shares Shorted | 4.47 M | ||||
| Price To Earning | 220.73 X | ||||
| Price To Book | 2.40 X | ||||
| Price To Sales | 4.77 X | ||||
| Revenue | 2.85 B | ||||
| Gross Profit | 2.27 B | ||||
| EBITDA | 650.53 M | ||||
| Net Income | 426.86 M | ||||
| Cash And Equivalents | 1.27 B | ||||
| Cash Per Share | 6.85 X | ||||
| Total Debt | 602.71 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 29.66 X | ||||
| Cash Flow From Operations | 572.84 M | ||||
| Short Ratio | 2.98 X | ||||
| Earnings Per Share | 2.21 X | ||||
| Price To Earnings To Growth | 0.49 X | ||||
| Target Price | 96.72 | ||||
| Number Of Employees | 3.04 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 13.61 B | ||||
| Total Asset | 6.99 B | ||||
| Retained Earnings | (194.69 M) | ||||
| Working Capital | 2.63 B | ||||
| Current Asset | 1.09 B | ||||
| Current Liabilities | 445.46 M | ||||
| Net Asset | 6.99 B |
About Biomarin Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomarin Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomarin Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomarin Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock: Check out Biomarin Pharmaceutical Piotroski F Score and Biomarin Pharmaceutical Altman Z Score analysis. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.